Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Irwin

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Diabetes/Metabolism Research and Reviews|February 23, 2007
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amideNigel Irwin, Paula L McClean, Roslyn S Cassidy, et al.
Biochimica Et Biophysica Acta|January 24, 2016
A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing propertiesVadivel Parthsarathy, Nigel Irwin, Annie Hasib, et al.
Pharmaceutical Development and Technology|March 14, 2017
Effect of poly(ethylene glycol) content and formulation parameters on particulate properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the double-emulsion evaporation procedureYusuf A Haggag, Ahmed M Faheem, Murtaza M Tambuwala, et al.
American Journal of Physiology. Endocrinology and Metabolism|February 15, 2007
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob miceFinbarr P M O'Harte, Kerry Hunter, Victor A Gault, et al.
Diabetes|July 28, 2005
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetesVictor A Gault, Nigel Irwin, Brian D Green, et al.
Biological Chemistry|January 15, 2004
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1Brian D Green, Victor A Gault, Nigel Irwin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2005
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetesNigel Irwin, Brian D Green, Mark H Mooney, et al.
Biological Chemistry|April 23, 2004
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analoguesBrian D Green, Victor A Gault, Mark H Mooney, et al.
Chemmedchem|June 11, 2015
Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 DiabetesNigel Irwin, Steven Patterson, Martin de Kort, et al.
Scientific Reports|August 4, 2019
Short-term CFTR inhibition reduces islet area in C57BL/6 miceDawood Khan, Ryan Kelsey, Rashmi R Maheshwari, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Diabetes/Metabolism Research and Reviews|February 23, 2007
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amideNigel Irwin, Paula L McClean, Roslyn S Cassidy, et al.
Biochimica Et Biophysica Acta|January 24, 2016
A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing propertiesVadivel Parthsarathy, Nigel Irwin, Annie Hasib, et al.
Pharmaceutical Development and Technology|March 14, 2017
Effect of poly(ethylene glycol) content and formulation parameters on particulate properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the double-emulsion evaporation procedureYusuf A Haggag, Ahmed M Faheem, Murtaza M Tambuwala, et al.
American Journal of Physiology. Endocrinology and Metabolism|February 15, 2007
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob miceFinbarr P M O'Harte, Kerry Hunter, Victor A Gault, et al.
Diabetes|July 28, 2005
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetesVictor A Gault, Nigel Irwin, Brian D Green, et al.
Biological Chemistry|January 15, 2004
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1Brian D Green, Victor A Gault, Nigel Irwin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2005
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetesNigel Irwin, Brian D Green, Mark H Mooney, et al.
Biological Chemistry|April 23, 2004
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analoguesBrian D Green, Victor A Gault, Mark H Mooney, et al.
Chemmedchem|June 11, 2015
Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 DiabetesNigel Irwin, Steven Patterson, Martin de Kort, et al.
Scientific Reports|August 4, 2019
Short-term CFTR inhibition reduces islet area in C57BL/6 miceDawood Khan, Ryan Kelsey, Rashmi R Maheshwari, et al.
Pageof 17